Borna disease virus induces acute fatal neurological disorders in neonatal gerbils without virus- and immune-mediated cell destructions  by Watanabe, Makiko et al.
Borna disease virus induces acute fatal neurological disorders in
neonatal gerbils without virus- and immune-mediated cell destructions
Makiko Watanabe,1 Byeong-Jae Lee, Makiko Yamashita, Wataru Kamitani,
Takeshi Kobayashi, Keizo Tomonaga,* and Kazuyoshi Ikuta
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan
Received 28 August 2002; returned to author for revision 21 November 2002; accepted 31 January 2003
Abstract
Borna disease virus (BDV) is a noncytolytic, neurotropic RNA virus that is known to cause neurological disturbances in various animal
species. Our previous experiment demonstrated that neonate gerbils develop an acute fatal neurological disease following infection with
BDV (Watanabe et al., 2001, Virology 282, 65–76). The study suggested that BDV directly causes functional damage of neuronal cells
resulting in the lethal disorder in neonatal gerbils. To extend this finding, we examined whether BDV can induce neurological diseases in
the absence of virus- and immune-mediated cell destruction, by using cyclosporine A (CsA)-treated neonatal gerbils. Although CsA
completely suppressed specific antibody production and brain inflammation in the infected gerbil brains, the fatal neurological disorder was
not inhibited by the treatment. Furthermore, we demonstrated that CsA treatment significantly decreased brain levels of cytokines, except
interleukin (IL)-1, in the infected gerbils. These results suggested that BDV replication, as well as brain cytokines, at least IL-1, rapidly
induces fatal disturbances in gerbil brain. We demonstrate here that BDV exhibits a unique neuropathogenesis in neonatal gerbil that may
be pathologically and immunologically different from those in two other established rodent models, rats and mice. With this novel rodent
model of virus infection it should be possible not only to examine acute neurological disturbances without severe neuroanatomical and
immunopathological alterations but also to analyze molecular and cellular damage by virus replication in the central nervous system.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Borna disease virus (BDV) is the prototype of a new
family, Bornaviridae, within the nonsegmented negative-
strand RNA viruses, Mononegavirales (de la Torre, 1994;
Schneemann et al., 1995), and is characterized by low virus
production, neurotropism, and nuclear localization of BDV
transcription and replication (Cubitt and de la Torre, 1994).
Although BDV was originally described as an agent of
nonpurulent encephalomyelitis in horses in Germany (Rott
and Becht, 1995), BDV infection has now been found in a
wide range of vertebrates, including sheep, cattle, cats, and
birds (Bode et al., 1994; Lundgren et al., 1995; Rott and
Becht, 1995). Recent epidemiological studies suggested that
BDV infection also occurs in humans and that it may be
related to certain human psychiatric diseases (Bode et al.,
1995; Sauder et al., 1996; Salvatore et al., 1997; Waltrip et
al., 1997; Nakamura et al., 2000).
At present, BDV neuropathogenesis has been extensively
studied in rodent models, of which the rat is the best-
characterized animal. In rats infected as adults with BDV,
cellular immune response appears critical to the develop-
ment of the neurological disorders characterized by loco-
motor abnormality (Narayan et al., 1983; Stitz et al., 1995;
Lewis et al., 1999; Planz and Stitz, 1999). In contrast,
neonatal rats do not show any immunopathological alter-
ations in the brains following BDV infection (Hirano et al.,
1983; Narayan et al., 1983). It has been demonstrated,
however, that infected neonatal rats develop abnormalities
in affective behavior and neuroanatomical disturbances
characterized by degeneration of hippocampal neurons, cor-
tical shrinkage, and cerebellar hypoplasia (Carbone et al.,
1991; Bautista et al., 1995; Eisenman et al., 1999; Rubin et
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al., 1999). Furthermore, chronic astrocytosis and microglio-
sis, as well as a progressive decrease in synaptic density and
plasticity, were observed in the brains of neonatally infected
rats (Gonzalez-Dunia et al., 2000). These observations have
indicated that BDV infection can induce neuronal degener-
ations and dysfunctions without an immune-mediated
mechanism. Therefore, neonatal rat infection is now con-
sidered to be a good model for understanding direct effects
of BDV infection on the neuronal cells of brain. On the
other hand, BDV may induce neuronal disturbances in neo-
natal rat brains by indirect routes, e.g., via altered expres-
sion of cytokines, tissue factors, nerve growth factors,
and/or neurotransmitters caused by the infection (Hornig et
al., 1999; Plata-Salaman et al., 1999; Sauder and de la
Torre, 1999; Pletnikov et al., 2000; Zocher et al., 2000). In
addition, mice are also frequently used for neuropathologi-
cal analysis of BDV infection. Specific strains of mice
exhibit severe neurological diseases following neonatal
BDV infection. In the case of neonate mouse infection, it
has been revealed that the neurological disorders are due to
the indirect damage caused by host immune responses (Hal-
lensleben et al., 1998; Hausmann et al., 1999).
Neonatal gerbils are emerging as an intriguing model for
analyzing direct damage of neuronal cells by BDV infection.
In a previous study, we demonstrated that despite development
of acute fatal neurological disorders and aggressive prolifera-
tion of BDV in infected newborn gerbils, no severe neuroana-
tomical alterations, including astrocytosis and neuronal degen-
eration, were observed in the brains (Watanabe et al., 2001).
From these results, we concluded that significant replication of
BDV in specific areas of the central nervous system (CNS)
contributes to the acute neurological disturbances in neonatal
gerbils. In the report, however, we could not exclude the
effects of infiltrations, antibody production, and cytokine ex-
pression in the infected neonates as secondary factors contrib-
uting to the lethal outcome. Although antibody and cytokine
production seems not to directly induce neurological disorders
in the BDV-infected rat model (Morimoto et al., 1996; Plata-
Salaman et al., 1999; Sauder and de la Torre, 1999; Furrer et
al., 2001), the roles of these brain factors in the induction of
acute fatal disorders in virus-infected neonates are not fully
understood.
In this study, to extend our knowledge regarding BDV-
induced acute fatal neurological disorders, we further ana-
lyzed BDV-infected neonatal gerbils to which an immuno-
suppressive agent, cyclosporine A (CsA), was administered.
Although CsA treatment could completely suppress anti-
body production and cell infiltration in the gerbil brains,
fatal neurological disorders in neonates were not at all
inhibited by the treatment. Moreover, the immunosuppres-
sion by CsA decreased the levels of brain cytokines, except
interleukin (IL)-1 in the infected gerbils. These results
suggested that, in addition to direct damage by BDV repli-
cation, expression of brain cytokines, at least IL-1, may
contribute to the induction of acute fatal disorders in the
gerbils in the absence of neuronal cell destruction. Impor-
tantly, we show the possibility that neonatal gerbil infection
is a unique and useful model for understanding acute neu-
rological disturbances without neuroanatomical and immu-
nopathological alterations.
Results
Neurological diseases in BDV-infected,
immunosuppressed neonatal gerbils
To investigate the role of host immune responses and cy-
tokine expression in BDV-induced neuropathogenesis, we in-
tracranially inoculated BDV into a total of 34 neonatal gerbils
with or without CsA treatment (Table 1). CsA was adminis-
tered daily from 15 days postinfection (dpi), because newborn
animals younger than neonatal day (ND) 15 were too imma-
ture to receive the treatment. Furthermore, because neonatally
BDV-infected gerbils do not show specific antibodies to BDV,
brain inflammation, and neurological disorders by the ND15
(Watanabe et al., 2001), it is not likely that some cellular
immune responses had occurred by ND15 that triggered a
cascade of events leading to the lethal outcome of the infected
neonates. After ND15, neither relaxation nor exacerbation of
symptoms was observed in the neonates treated with CsA.
Almost all gerbils treated with any dose of CsA, as well as
non-CsA-treated gerbils, developed acute and severe clinical
disease around ND22 (Table 1). The neurological disorders are
Table 1










UI-0 (n  10)  0 0  
UI-20 (n  3)  20 0  
I-0 (n  9)  0 100  
I-5 (n  4)  5 100  
I-10 (n  4)  10 100  
I-20 (n  4)  20 100  
a Incidence of BDV-specific neurological disorders observed in gerbils at 25 dpi.
b Antibody to BDV P protein was measured by ELISA (Watanabe et al., 2000). Detailed titers of antibody are shown in Fig. 1.
c Induction of infiltrations was estimated by HE staining (Fig. 2) of the gerbil brains at 25 dpi , none; , minimal; , modulate.
246 M. Watanabe et al. / Virology 310 (2003) 245–253
marked by paralysis of the hind legs with significant body
weight loss until 25 dpi, as reported previously (Watanabe et
al., 2001). In addition, quadriparesis, hypopraxia, debility and
blindness were induced after the onset of the disease in some
gerbils. During the observation period, none of the gerbils
recovered from the disease. All of the diseased gerbils died by
day 30 postinfection.
Suppression of BDV-specific antibody production in
cyclosporine A-treated gerbils
To examine whether CsA treatment suppresses the hu-
moral immune response against BDV infection, we deter-
mined the antibody titer to BDV 24-kDa phosphoprotein (P)
in the infected gerbils by antigen capture enzyme-linked
immunosorbent assay (ELISA) at 25 dpi. As shown in Fig.
1, non-CsA-treated neonatal gerbils produced virus-specific
antibody at high levels. In CsA-treated, infected gerbils, the
titer was drastically decreased in a CsA dose-dependent
manner. At a dose of 20 mg/kg CsA, no antibody production
could be observed in infected gerbils (Fig. 1, Table 1). This
result reveals that CsA treatment successfully inhibits the
humoral immune response in infected gerbils, indicating
that antibodies are not involved in neurological diseases
observed in infected neonates.
Effects of cyclosporine A treatment in BDV-induced
pathological alterations and viral replication in
gerbil brains
In a previous study, we demonstrated that no gross neu-
roanatomical disturbances were observed in the brains of
neonatally infected gerbils. In this experiment, we also
found minimal perivascular and meningeal infiltrations by
hematoxylin–eosin (HE) staining in the cerebral cortex,
diencephalon, and cerebellum in neonatally infected gerbils
not treated with CsA (Fig. 2A, b and e). With CsA treat-
ment, however, no inflammation was detected in the brains
at day 25 postinfection (Fig. 2A, c and f). Furthermore, we
could not find any histological alternations in the BDV-
infected, CsA-treated brains (Fig. 2B, b and d). As demon-
strated in the previous study, no apoptotic signal was dem-
onstrated in the brain sections from infected gerbils by
terminal TUNEL assay (data not shown).
We investigated whether immunosuppression caused by
CsA treatment could affect replication of BDV in gerbil brains.
The virus-specific mRNAs were detected in gerbil brains by
Northern blot analysis and in situ hybridization (ISH). As
shown in Fig. 3, BDV P mRNA was comparatively detected in
CsA-treated and nontreated, infected gerbil brains at 25 dpi
(Fig. 3A). ISH using an antisense probe also revealed efficient
viral gene production in the brains from both CsA-treated and
nontreated, gerbils at the same level (Fig. 3B). The BDV sense
probe for ISH also revealed no differences between the CsA-
treated and nontreated gerbil brains (data not shown). Further-
more, as reported previously, viral mRNAs were found pre-
dominantly in the cerebellum and lower brainstem of diseased
neonates at 25 dpi (Fig. 3B). These results demonstrated that
CsA treatment has no effect on viral replication in the brains of
infected newborn gerbils.
Cytokine expression in neonatally infected gerbil brains
Previous studies using a rat model demonstrated that
brain cytokines may play a role in BDV-induced neuro-
pathogenesis (Shankar et al., 1992; Hornig et al., 1999;
Plata-Salaman et al., 1999; Sauder and de la Torre, 1999). It
has been also suggested that cytokines may be directly
activated in CNS resident cells by BDV infection, even in
immunoincompetent rats (Morimoto et al., 1996). There-
fore, to understand the role of brain cytokines in severe
neurological disorders of BDV-infected neonatal gerbils,
we investigated expression of cytokine mRNAs in BDV-
infected gerbil brains. To detect brain cytokines of gerbils,
we first cloned and sequenced several cytokine cDNAs,
including IL-1, IL-1, IL-2, IL-4, interferon (IFN)-, tu-
mor necrosis factor (TNF)-, and transforming growth fac-
tor (TGF)-, specific for gerbil, and designed specific prim-
ers and probes for them. The gerbil-specific primers and
probes used in this study are summarized under Materials
and Methods. The alteration of cytokine expression was
analyzed in the cerebral cortex and cerebellum at 25 dpi by
semiquantitative reverse transcription (RT)-PCR followed
by Southern blot hybridization. As shown in Fig. 4, IL-1,
IL-1, and IFN- mRNAs were markedly increased in the
brains of infected gerbils, whereas upregulation of IL-4 and
TNF- mRNAs was detected in only a few infected gerbils
(Fig. 4). On the other hand, although expression of TGF-
mRNA slightly increased in the cerebellum of infected
gerbils, both the cerebral cortex and cerebellum contained
significant levels of the mRNA, even in uninfected gerbil
brains (Fig. 4). These observations demonstrate that upregu-
lations of IL-1, IL-1, and IFN- may be a characteristic
of BDV-infected newborn brains.
Fig. 1. Inhibition of antibody production in BDV-infected, CsA-treated
neonatal gerbils. Sera from BDV-infected, CsA-treated neonatal gerbils
were collected at ND25. Anti-BDV-P antibody production was estimated
by antigen capture ELISA (Watanabe et al., 2000). Values were expressed
as means  SEM.
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CsA treatment altered cytokine levels in the CNS of
BDV-infected neonatal gerbils (Fig. 4). The level of IL-1
mRNA was significantly decreased in the cerebellum of
CsA-treated gerbils. Furthermore, we noted a marked re-
duction in IFN- mRNA in the treated brains. Interestingly,
induction of IFN- mRNA in a gerbil brain was completely
suppressed by treatment (Fig. 4). Although the downregu-
lation of IFN-, as well as that of IL-4 and TGF-, is not
statistically significant, it was not necessarily linked to the
induction of the neurological disorder in gerbils (Fig. 4). On
the other hand, expression of IL-1 in infected brains was
not affected by treatment with the immunosuppressive agent
at 25 dpi (Fig. 4). We repeated the RT-PCR analysis at least
four times in each gerbil brain and obtained similar results
in each experiment. Together with the deleterious effects of
IL-1 on neuronal cell functions (Neveu and Liege, 2000;
Konsman et al., 2002), these results suggest the possibility
that expression of brain cytokines, at least IL-1, contrib-
utes to the induction of fatal neurological disorders in new-
born gerbils in the absence of neuronal cell destruction.
Discussion
In this study, we demonstrated that CsA treatment on a
daily basis from ND15 could completely suppress antibody
Fig. 2. Neuropathological analysis of BDV-infected, CsA-treated gerbil brains. (A) Brain sections from uninfected gerbil (a, d), BDV-infected gerbil (b, e), and
BDV-infected, CsA-treated gerbils (20 mg/kg, I-20) (c, f) at 25 dpi were stained with HE. Cerebral cortex (a–c) and cerebellum (d–f) are shown. Infiltrated cells
were observed in the cerebral cortex and meninges of BDV-infected, vehicle-treated gerbils but not CsA-treated animals. (B) HE staining of brain sections from
uninfected gerbil (a, c) and BDV-infected, CsA-treated gerbils (20 mg/kg; I-20) (b, d) at 25 dpi. Cerebral cortex (a, b) and hippocampus (c, d) are shown.
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production and cell infiltration in BDV-infected neonatal
gerbils (Table 1, Figs. 1 and 2). However, the immunosup-
pression did not inhibit development of the fatal disorders in
infected animals at all. These results indicate that antibody
production and immune-mediated cell infiltration are not
likely to be associated with the acute neurological diseases
of BDV-infected neonatal gerbils.
In neonatal gerbils, both the direct and indirect effects of
BDV infection could be involved in the acute fatal disor-
ders. Disruption of the specialized cell functions by viral
replication is most likely responsible for direct neurological
disturbances in neonatal gerbil brains. Indeed, recent studies
have demonstrated that BDV infection could affect several
cellular factors and inhibit some cellular functions, such as
cell process outgrowth and glutamate uptake, in cultured
neural cells (Billaud et al., 2000; Kamitani et al., 2001;
Hans et al., 2001; Planz et al., 2001). In addition to the
previous study, we again found here that significant BDV
replication in specific CNS areas, especially in the Purkinje
cells of the cerebellum and brainstem, is closely linked to
the onset of the disease (Fig. 3). This observation provides
us with the possibility that BDV replication has deleterious
effects on neuronal functions in these regions, leading to
fatal neurological disorders. The cerebellum is one of the
brain regions that develop late and to a large extent post-
natally. In the early postnatal weeks, Purkinje cells progres-
sively lose the input from several climbing fibers and mossy
fibers via granule cells. Furthermore, there is a reduction in
Purkinje cell apical cone and dendrite growth, as well as in
synaptogenic rate between mossy fibers and granule cells, in
the maturation period. Interestingly, it has been known that
Purkinje cells change their susceptibility to some viruses
during this maturation period (Oliver et al., 1997). Consid-
ering that the Purkinje cells of the neonatal gerbils did not
show BDV-positive signals until postnatal week 3 and were
not destroyed by BDV infection, it is possible that BDV can
infect only mature Purkinje cells of gerbils and disrupt some
critical functions of the cells in the early maturation stage.
On the other hand, the role of cytokines is widely dis-
cussed in virus-infected CNSs as factors indirectly respon-
sible for the induction of neurological dysfunction (Zhao
and Schwartz, 1998; Neveu and Liege, 2000; Konsman et
al., 2002). It is therefore likely that the altered levels of
brain cytokines also play important roles in BDV-induced
neurological abnormalities in infected gerbil brains. At
present, however, it is difficult to assess the neurobiochemi-
cal status of infected gerbil brain, because only limited
information and reagents, including gene sequences and
antibodies to the brain factors, are available for gerbils. In
this study, we selected several cytokines, that are relevant to
an understanding of BDV pathogenesis and cloned cDNAs
of them to use in further experiments. By using gerbil-
specific primers, we detected marked alterations in expres-
sion levels of cytokine mRNAs in the brains of ND1-
infected gerbils (Fig. 4). Expression of IL-1, IL-, IL-4,
TNF-, and IFN- mRNAs was upregulated in infected
gerbil brains on examination at 25 dpi, as in cases of rat
infection (Shankar et al., 1992; Morimoto et al., 1996;
Hornig et al., 1999; Plata-Salaman et al., 1999; Sauder and
de la Torre, 1999). Since CsA treatment suppressed invad-
ing immune-reactive cells and clearly depressed mRNA
levels of some cytokines, including IL-4, IFN-, and
TNF-, it is likely that these cytokines are derived mainly
from those invading cells. Incomplete depression of these
cytokines might be due to a very low level of inflammatory
cells, which were not detected after HE staining. On the
other hand, expression of IL-1 and -1 mRNAs was not
affected by CsA treatment in cerebral cortex and both ce-
rebral cortex and cerebellum, respectively, indicating that
these cytokines could be directly induced by BDV infection
of CNS resident cells. Considering that CsA treatment could
not inhibit the neurological diseases in the gerbils, the cy-
tokines, of which expression was not altered by the treat-
ment, may be involved in indirect effects on the neuronal
abnormalities in the gerbil brains. In our experiment, IL-1,
Fig. 3. Immunosuppression does not influence BDV replication in gerbil
brains. (A) Northern blot hybridization. Aliquots of 5 g of total RNA
from cerebral cortex (a) and cerebellum (b) were separated by denaturing
formaldehyde agarose gel electrophoresis, transferred to nylon membrane,
and hybridized with a BDV P antisense probe. UI-0, uninfected vehicle-
treated gerbils; UI-20, uninfected, CsA-treated gerbils (20 mg/kg); I-0,
BDV-infected, vehicle-treated gerbils; I-20, BDV-infected, CsA-treated
gerbils (20 mg/kg). (B) ISH. Sections of brains from uninfected gerbils
(UI-0; a, d), BDV-infected gerbils (I-0; b, e), and BDV-infected, CsA-
treated gerbils (20 mg/kg) (I-20; c, f) were hybridized with P antisense
probe. (a–c) cerebellum; (d–f) lower brainstem.
249M. Watanabe et al. / Virology 310 (2003) 245–253
especially IL-1, appeared to be a relevant candidate for the
indirect effects. Although the downregulation of IL-4,
IFN-, and TGF- (cortex) mRNAs was also insignificant
in the brains, these cytokines could not play critical roles in
the induction of neurological diseases, because the expres-
sion of these cytokines was not necessarily correlated with
the induction of neurological disorders in the gerbils. Note
that there remains the possibility that a different class of
brain molecules, expression of which was not examined in
this study, may play more of a role in the fatal disorder of
the gerbils.
Recently, several lines of evidence have suggested that
IL-1 is involved not only in normal CNS development but
also in induction of neurological diseases (Neveu and Liege,
2000; Konsman et al., 2002). It has been reported that
expression of IL-1 is increased in several neurodegenerative
disorders, such as multiple sclerosis, Parkinson’s disease,
and Alzheimer’s disease (Zhao and Schwartz, 1998; Roth-
well and Luheshi, 2000). Although such an increase in IL-1
in brains might reflect a response to ongoing CNS damage
and/or neuroprotective effects, there is growing evidence to
suggest a close link between IL-1 expression and these
Fig. 4. Expression of cytokine mRNAs in BDV-infected, immunosuppressed gerbil brains. (A) Expressions of brain cytokines (IL-1, IL-1, IL-4, IFN-,
TNF-, TGF-) in the cerebral cortex and cerebellum of BDV-infected newborn gerbils. The levels of cytokine mRNAs were analyzed with semiquantitative
RT-PCR and DNA blot hybridization as described under Materials and Methods. For semiquantitative RT-PCR, PCR amplification was conducted in 30
cycles for IL-1, IL-1, IFN-, and TGF- and 35 cycles for IL-4 and TNF-. UI-0, uninfected vehicle-treated gerbils; UI-20, uninfected, CsA-treated gerbils
(20 mg/kg); I-0, BDV-infected, vehicle-treated; I-20, BDV-infected, CsA-treated (20 mg/kg). Samples of three individuals from each group are shown. (B)
The quantitative analysis of cytokine expressions. The band intensities from (A) were determined by NIH Image. Values were normalized to -actin mRNA
levels. Values were expressed as means  SEM. Significant differences in BDV-infected, CsA-treated gerbils (I-20) compared with vehicle-treated gerbils
(I-0): *P  0.02, **P  0.01 (Student’s t test).
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disease (Zhao and Schwartz, 1998; Rothwell and Luheshi,
2000). An abnormal level of IL-1 might cause fragility of
neuronal cells in the CNS rather than neuronal protection. In
fact, it has been reported that IL-1-deficient mice are
resistant to fatal neuroadapted Sindbis virus (NSV) inocu-
lation into the cerebrum (Liang et al., 1999). This report
demonstrated that IL-1 deficiency protects against lethal
NSV encephalitis by a mechanism that does not involve the
inhibition of virus-induced CNS apoptosis, which is sug-
gestive of deleterious effects induced by IL-1 in acute
CNS damage including virus infection. Thus, further studies
to examine the role of IL-1 in BDV neuropathogenesis may
be warranted. Furthermore, the fact that neonatal rats in-
fected with BDV exhibit a sustained upregulation of IL-1
in the absence of a severe neurological disorder suggests
that both direct damage by BDV replication and an indirect
effect of cytokine upregulation in the brain may be required
for induction of the acute fatal disorders.
The neuropathological and neurological outcomes in BDV-
infected neonatal gerbils were totally different from those seen
in rats or mice. In neonatal rat infection, BDV causes a life-
long persistent infection with significant viral load in the brains
(Hirano et al., 1983; Narayan et al., 1983). BDV-infected
neonatal rats rarely show clinical manifestations and death.
Their brain development, however, is markedly disrupted in
specific brain regions (Carbone et al., 1991; Bautista et al.,
1995; Eisenman et al., 1999; Rubin et al., 1999). These degen-
erations in the CNS must result in distinct deficiencies in
emotional and cognitive functions observed in the infected rats.
Very recently, Nishino et al. (2002) have reported that a
mouse-passaged variant of BDV induces an acute fatal neuro-
logical disease in newborn Lewis rats. Although the neurolog-
ical symptoms and replication area of BDV in the infected
newborn rats were very similar to those in the neonatal gerbils
observed in this study, the rats exhibited rapid degeneration of
the hippocampal pyramidal neurons (Nishino et al., 2002). On
the other hand, specific strains of neonate mice infected with
BDV show severe, frequently fatal, neurological diseases (Hal-
lensleben et al., 1998), which are very similar to disorders in
neonatally infected gerbils. In neonatal mice, however, it has
been revealed that the severe diseases are due to a cytotoxic
T-cell-mediated immunopathological process (Hallensleben et
al., 1998; Hausmann et al., 1999). Considering the differences
in neonate models of BDV infection, the gerbil may provide a
good model not only to gain an understanding of acute neuro-
logical abnormalities without cell destruction but also to ana-
lyze molecular damage to neuronal cells directly induced by
virus replication in the CNS.
We demonstrate here that BDV has a unique neuropatho-
genesis in neonatal gerbils that may be pathologically and
immunologically different from that in two other estab-
lished rodent models, rats and mice. The effort to develop
new animal models for complex brain disturbances will
provide novel insights into the mechanisms by which neu-
rotropic viruses and/or soluble brain factors impair cellular
function without CNS destruction.
Materials and methods
Virus stock
Lewis rats were intracranially inoculated with BDV
(He/80 strain) (Cubitt et al., 1994) and sacrificed 3 weeks
after inoculation. Rat brains were homogenized in phos-
phate-buffered saline (PBS) and lysed by sonication. The
lysate was clarified by centrifugation and frozen at 80°C
as a virus source. Viral titer was calculated by indirect
immunofluorescence assay as previously described (Wa-
tanabe et al., 2001).
BDV infection and immunosuppression of gerbils
Neonatal gerbils were intracranially inoculated with 50 fo-
cus-forming units of BDV within 24 h of birth. CsA (Sandim-
mune, Novartis Phama AG, Switzerland; 5, 10, or 20 mg/kg
per day) or the same volume of vehicle (corn oil, Wako, Japan)
was orally administered on a daily basis from ND15. Almost
all gerbils examined were sacrificed 25 days after inoculation.
ELISA
Microtiter plates were coated with 100 l of PBS contain-
ing 5 g of purified P recombinant protein for 14 h at 4°C. The
plates were subsequently blocked with 150 l of 0.5% skim
milk in PBS for 3 h at 37°C. After three washes with 0.05%
Tween-20 in PBS (PBST), the wells were incubated with 100
l of serially diluted (1:100 to 1:12,800) gerbil serum for 1 h
at 37°C. After five washes with PBST, the wells were incu-
bated with 50 l of 1:2000 diluted HRP-conjugated anti-
mouse IgG (Jackson ImmunoResearch Laboratories Inc.) for
1 h at 37°C. After washing, 100 l of 0.4 mg/ml o-phenylen-
diamine with hydrogen peroxide was added. After color de-
velopment for 1 min, 100 l of 3 N H2SO4 was added.
Antibody titer was defined as the final dilution at the point that
the absorbance exceeded 0.3.
Histological analysis
Gerbil brains were fixed in 4% paraformaldehyde in PBS
and embedded in paraffin. Thin sections (6 m) were
stained with hematoxylin and eosin for histological evalu-
ation by light microscopy.
ISH
Thin sections (4 m) of gerbil brains were deparaffinized
and incubated in Tris–HCl before being treated with 0.1
mg/ml proteinase K in TE buffer for 20 min at 37°C and then
fixed with 4% paraformaldehyde in Tris–HCl (pH 7.5). The
sections were then incubated with hybridization solution (50%
formamide, 3x SSC, 50 mM Hepes, pH 7.0, 5x Denhadt’s
solution, 250 g/ml salmon sperm DNA) for 30 min at 37°C
and were hybridized by incubation with a 10 g/ml final
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concentration of digoxigenin (DIG)-labeled riboprobes for
16 h at 50°C. After hybridization, sections were washed and
incubated with alkaline phosphatase-labeled anti-DIG anti-
body. Specific signals were visualized with nitroblue tetrazo-
lium and X-phosphate (Boehringer-Mannheim).
Cloning and sequencing of gerbil-specific cytokine cDNAs
Total RNA was isolated from gerbil brain homogenates
using an RNA isolation kit (Nippon Gene Co., Tokyo,
Japan). Aliquots of 0.8 g of total RNA, 100 pmol of
oligo(dT)16 primer, and 50 units of MultiScribe reverse
transcriptase (RT) (PE Applied Biosystems, Norwalk, CT,
USA) were incubated at 25°C for 10 min, 48°C for 30 min
for RT, and then 95°C for 5 min for RT inactivation.
Two-microliter aliquots of the resulting cDNAs were used
as templates for PCR amplification. The PCR was per-
formed with 30 cycles at 95°C for 30 s, 50°C for 30 s, and
72°C for 1 min with Taq DNA polymerase (Takara Ex Taq;
Takara, Tokyo, Japan). PCR primers used for gerbil cyto-
kines were as follows:
IL-1-sense 5-CAG AAT TCC TTC TAT GAT GCA AG-3
IL-1-antisense 5-TCG GAT CCC TGA GCA CTC ACA-3
IL-1-sense 5-TTG AAT TCC TTC ATC TTT GAA GAA GAG CC-3
IL-1-antisense 5-TGG GAT CCA CAC TCT CCA GCT GCA G-3
IL-2 sense 5-CAA GGA TCC GAA ACT CCC CA-3
IL-2 antisense 5-CTC AGG AAT TCC ACC ACA GT-3
IL-4-sense 5-CAC ATC CCT GAC GGT AGA ATT C-3
IL-4-antisense 5-CTG AGG ATC CCG GAG TTG TTC T-3
TNF--sense 5-ACT GGA ATT CGG GGT GTT TGG TC-3
TNF--antisense 5-GAG AAC CTG GGA ATT CAC GAG G-3
IFN--sense 5-TGG AAT TCT ACT AGA GAA GAC ACA TCA GC-3
IFN--antisense 5-ATG GAT CCG ACT CCT TTT CCG CTT C-3
TGF--sense 5-ACC TGG GCT GGA AGT GGA TC-3
TGF--antisense 5-ATG AAT TCT TGC GGC CCA CGT AGT AGA-3
PCR products were digested with EcoRI and BamHI and
cloned into pBluescript II SK() vector. Cloned cDNAs of
gerbil cytokine fragments were sequenced with the Thermo
Sequenase Cy5.5 dye terminator cycle sequencing kit (Am-
ersham Pharmacia Biotech, Uppsala, Sweden).
Semiquantitative RT-PCR analysis of cytokine expression
Expression of IL-1, IL-1, IL-2, IL-4, TNF-, IFN-, and
TGF- mRNAs in BDV-infected gerbil brains was examined
by semiquantitative RT-PCR followed by Southern blot hy-
bridization. First-strand cDNAs were synthesized from ali-
quots of 1 g of total RNA of gerbil brains. PCR amplification
was performed in a total volume of 25 l containing 2 l of
cDNA and 1.25 U of Taq polymerase (Amplitaq Gold; Perkin–
Elmer). The serial dilutions of positive controls for each gene
were amplified at 20, 25, 30, and 35 cycles to determine the
optimal number of amplification cycles that produces a liner
relationship between input RNA and PCR product. The PCR
amplification was then conducted in 30 cycles (for IL-1,
IL-1, IL-2, IFN-, and TGF-) or 35 cycles (for IL-4 and
TNF-) under the conditions described above. As a control for
RNA input, levels of -actin (primers: 5-ATG GTG GGA
ATG GGT CAG AAG-3 and 5-ACG CAC GAT TTC CCT
CTC AGC T-3) were assayed. The amplification products
were resolved on 1.5% agarose gels and transferred onto nylon
membranes. The membranes were then analyzed by Southern
blot hybridization with DIG-labeled specific probes for gerbil
cytokines. The intensity of each band on X-ray films was
quantified using NIH Image. The statistical significance of the
expression level of each cytokines was determined with Stu-
dent’s t test using the Statcel software (OME Publishing Inc,
Tokyo, Japan).
Northern blot analysis
We detected BDV RNAs in the gerbil brains by Northern
(RNA) blot analysis using a BDV-P antisense probe as
described previously (Watanabe et al., 2001). Briefly, the
total RNAs were electrophoresed through 1% agarose gel,
transferred onto nylon membrane, and hybridized with P
antisense DIG-labeled probe. The signals were detected
with anti-DIG antibody and chemiluminescence substrate
and visualized by exposure to X-ray film.
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